Stock Analysis on Net

Abiomed Inc. (NASDAQ:ABMD)

This company has been moved to the archive! The financial data has not been updated since November 3, 2022.

Cash Flow Statement 
Quarterly Data

The cash flow statement provides information about a company cash receipts and cash payments during an accounting period, showing how these cash flows link the ending cash balance to the beginning balance shown on the company balance sheet.

The cash flow statement consists of three parts: cash flows provided by (used in) operating activities, cash flows provided by (used in) investing activities, and cash flows provided by (used in) financing activities.

Abiomed Inc., consolidated cash flow statement (quarterly data)

US$ in thousands

Microsoft Excel
3 months ended: Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016
Net income (loss) 106,133 54,554 60,325 45,752 56,953 (26,525) 56,856 61,868 62,213 44,588 31,798 69,217 13,071 88,923 73,960 44,863 50,127 90,066 36,847 13,446 24,503 37,374 14,899 15,432 8,875 12,910
Depreciation and amortization 6,724 6,620 7,290 6,926 6,966 6,907 6,826 6,134 5,657 5,480 6,003 5,375 4,687 4,365 4,185 3,589 3,388 2,959 2,905 2,780 2,857 2,463 1,714 1,530 1,552 1,406
Acquired in-process research & development 496 115,490
Bad debt expense (recoveries) 74 11 65 8 32 (59) 66 181 (96) (277) 246 89 173 (21) 142 111 279 188 46 46 (12) (42) 171 1 18 (31)
Stock-based compensation 16,014 13,362 11,989 12,383 15,749 12,608 13,287 12,856 11,565 9,298 2,762 10,574 13,324 13,121 10,737 15,578 15,934 12,245 11,183 11,232 9,282 8,656 8,345 6,474 9,650 8,397
Write-down of inventory and other 4,540 2,570 9,094 2,704 2,687 3,508 3,440 1,956 1,405 1,717 265 1,827 898 1,259 1,100 1,419 836 897 734 684 2,018 510 1,026 705 646 708
Accretion on marketable securities (268) 587 954 933 850 918 794 710 379 94 (53) (402) (970) (1,306) (1,100) (796) (485) (363)
Change in fair value of other investments (77,095) (278) (8,608) 8,175 (4,792) (17,648) (7,876) (9,235) (10,049) (23,823) 22,591 (23,350) 45,597 (39,654) (30,161)
Gain on previously held interest in preCARDIA (20,980)
Excess tax benefit from stock-based awards (7,443) (964) (2,590) (1,041)
Deferred tax provision (1,043) (6,373) (4,636) (1,144) 1,894 6,299 6,460 8,733 1,241 12,946 2,402 20,356 (581) 10,776 18,247 19,684 (1,213) (44,463) 7,884 31,667 6,903 (3,830) 6,986 9,040 2,777 7,000
Change in fair value of contingent consideration (3,156) (3,359) (29) (941) (763) 871 (610) 899 1,316 801 (1,440) 204 305 356 (1,008) 90 162 (159) 67 588 417 265 978 426 10 176
Other non-cash operating activities 476 1,080 554 778 802 751 970 1,186 1,038 970 941 990 1,174 1,003
Accounts receivable (4,521) (1,881) (2,327) 218 (1,319) 8,763 (5,134) (11,692) 1,753 3,014 15,884 (6,505) (8,629) 4,801 (2,755) (14,137) (7,061) 1,930 (4,947) (7,518) (3,619) 795 (3,995) (3,748) (5,324) 1,517
Inventories (11,836) (6,510) (9,754) (7,896) (5,903) (5,770) (4,061) 525 6,282 (211) 24 (1,057) (4,965) (7,239) (10,659) (9,772) (8,956) (7,794) (3,712) (6,611) (4,061) (1,302) (3,669) (2,331) (2,891) (3,393)
Prepaid expenses and other assets (16,266) 3,117 3,468 8,426 (11,603) (8,697) 6,029 (8,805) 1,259 485 (1,083) (173) (660) (3,417) (3,205) 2,665 144 (2,131) (3,433) (164) 46 (915) 1,557 (1,894) (2,036) 7
Accounts payable 132 1,438 3,122 3,785 (1,504) (4,762) 10,776 1,981 (5,670) (4,458) 1,740 60 2,244 (1,463) 3,067 4,148 (1,923) 2,684 1,817 2,296 4,690 (4,391) 4,023 1,636 2,051 (145)
Accrued expenses and other liabilities (8,991) 5,583 5,829 9,001 447 (16,037) (4,632) 11,988 (2,404) (19,584) 4,483 12,461 5,375 (6,643) 6,497 6,083 7,402 (6,576) 3,848 7,048 (738) (2,436) 11,183 7,883 4,109 (952)
Deferred revenue 2,504 (2,418) 1,636 883 76 (278) 3,284 (150) 1,320 719 30 (226) 3,216 (233) 1,344 1,090 1,926 (2,852) 3,160 1,202 871 (853) 1,480 (65) 509 (179)
Changes in assets and liabilities (38,978) (671) 1,974 14,417 (19,806) (26,781) 6,262 (6,153) 2,540 (20,035) 21,078 4,560 (3,419) (14,194) (5,711) (9,923) (8,468) (14,739) (3,267) (3,747) (2,811) (9,102) 10,579 1,481 (3,582) (3,145)
Adjustments to reconcile net income (loss) to net cash provided by operating activities (92,712) 13,549 18,647 44,735 3,619 81,884 29,619 17,267 14,996 (12,829) 54,795 20,223 61,188 (24,295) (3,569) 29,752 10,433 (43,435) 19,552 43,250 18,654 (1,080) 22,356 18,693 8,481 13,470
Net cash provided by operating activities 13,421 68,103 78,972 90,487 60,572 55,359 86,475 79,135 77,209 31,759 86,593 89,440 74,259 64,628 70,391 74,615 60,560 46,631 56,399 56,696 43,157 36,294 37,255 34,125 17,356 26,380
Purchases of marketable securities (150,721) (121,897) (205,301) (248,017) (194,811) (139,021) (68,446) (193,195) (232,492) (62,066) (119,767) (223,028) (144,418) (124,067) (119,857) (128,789) (88,254) (24,702) (115,574) (77,900) (58,308) (73,626) (100,910) (43,356) (66,917) (67,318)
Proceeds from the sale and maturity of marketable securities and other 218,286 141,385 139,320 77,675 202,695 123,823 58,312 118,134 80,384 139,813 140,332 147,575 169,701 93,180 104,937 90,105 61,062 75,782 58,814 52,679 28,794 66,622 60,812 27,985 69,595 47,090
Purchases of other investments (384) (4,591) (11,702) (3,201) (3,866) (23,004) (1,100) (2,000) (58) (13,099) (5,000) (2,800) (12,299) (19,010) (10,260) (1,166) (6,000) (400) (2,750) (149)
Acquisition of preCARDIA, net of cash acquired (82,821)
Acquisition of Breethe, net of cash acquired (236) (51,947)
Proceeds from sale of Shockwave Medical securities 39,995 67,882
Purchases of property and equipment (5,609) (6,783) (14,891) (6,478) (7,224) (7,170) (26,109) (7,722) (9,508) (10,044) (10,546) (8,853) (12,357) (12,250) (8,535) (8,124) (12,198) (15,147) (11,695) (26,493) (7,871) (9,804) (26,376) (13,586) (5,354) (5,099)
Net cash (used for) provided by investing activities 101,567 8,114 (92,574) (180,021) 660 (109,055) (36,243) (105,787) (95,070) 13,756 9,961 (97,405) 7,926 (45,937) (35,754) (65,818) (49,650) 34,767 (68,455) (51,714) (43,385) (17,208) (69,224) (29,106) (2,676) (25,327)
Proceeds from the exercise of stock options 468 1,531 602 440 6,262 2,120 1,999 1,521 4,545 1,010 583 459 1,446 1,260 1,906 430 4,815 5,798 1,677 2,369 1,702 3,555 2,395 2,501 2,994 2,770
Excess tax benefit from stock-based awards 7,443 964 2,590 1,041
Taxes paid related to net share settlement upon vesting of stock awards (1,852) (10,950) (130) (4,267) (2,539) (9,590) (135) (242) (1,077) (9,857) (80) (401) (670) (40,536) (563) (1,547) (2,068) (67,598) (457) (623) (1,432) (17,805) (207) (290) (4,575) (15,033)
Payment of Breethe contingent consideration at acquisition date fair value (2,334)
Repurchase of common stock (112,106) (14,517) (11,310) (25,003) (25,003) (34,873)
Proceeds from the issuance of stock under employee stock purchase plan 3,308 4,273 2,961 3,501 1,978 2,735 2,368 1,676 1 1,375 1,331 1,063 951 769
Principal payments on capital lease obligation (140) (193) (184) (182) (181) (83)
Net cash provided by (used for) financing activities (110,182) (23,936) 4,745 (6,161) 6,684 (7,470) 5,365 1,279 5,446 (20,157) (21,765) (24,945) (31,729) (39,276) 3,019 (1,116) 4,122 (61,800) 2,551 1,606 1,140 (14,434) 10,400 2,994 1,695 (11,222)
Effect of exchange rate changes on cash and cash equivalents (2,963) (4,607) (2,580) (1,932) (1,488) 3,910 (3,905) 4,150 (171) (2,872) (418) 601 (1,225) 612 (816) 118 62 (1,285) 1,978 (622) (346) 278 (460) (1,653) 60 212
Net increase (decrease) in cash and cash equivalents 1,843 47,674 (11,437) (97,627) 66,428 (57,256) 51,692 (21,223) (12,586) 22,486 74,371 (32,309) 49,231 (19,973) 36,840 7,799 15,094 18,313 (7,527) 5,966 566 4,930 (22,029) 6,360 16,435 (9,957)

Based on: 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-K (reporting date: 2022-03-31), 10-Q (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-K (reporting date: 2021-03-31), 10-Q (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-K (reporting date: 2020-03-31), 10-Q (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-K (reporting date: 2019-03-31), 10-Q (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-K (reporting date: 2018-03-31), 10-Q (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-K (reporting date: 2017-03-31), 10-Q (reporting date: 2016-12-31), 10-Q (reporting date: 2016-09-30), 10-Q (reporting date: 2016-06-30).


Net income (loss)
The net income fluctuates considerably across quarters, with significant increases noted around mid-2018 and early 2019, reaching highs above $90 million. However, there are fluctuations with some quarters showing reduced profitability or losses, notably in the first quarter of 2021 and in late 2019. The trend from late 2020 through 2022 shows recovery and growth, culminating in a peak of $106 million in September 2022.
Depreciation and amortization
This expense generally escalates over time, beginning at around $1.4 million and steadily rising to approximately $6.7 million by late 2022, suggesting increased investments in fixed assets or capitalized intangible assets.
Stock-based compensation
Stock-based compensation expenses show variability but generally trend upward, with intermittent spikes. A notably low value appeared in the first quarter of 2020; however, the overall pattern suggests increasing costs related to equity incentives, reaching around $16 million in late 2022.
Write-down of inventory and other
This item shows irregular but rising values, with a significant peak in the third quarter of 2022 surpassing $9 million. Earlier quarters show moderate to high inventory write-downs, indicating periodic adjustments and potential challenges in inventory management or valuation.
Bad debt expense (recoveries)
Bad debt expense is relatively minimal throughout, with small positive and negative fluctuations, indicating occasional recoveries or minor expenses related to receivables.
Deferred tax provision
This item is highly volatile, with substantial fluctuations between positive and negative values. Notable positive spikes occur intermittently, whereas large negative spikes may reflect tax planning or adjustments affecting tax liabilities.
Change in fair value of other investments
From 2018 onwards, significant fluctuations are observed with extreme negative and positive values alternating, indicating marked volatility in investment valuation that impacts the financial results significantly.
Acquisition-related items
There are large one-time acquisitions reflected in late 2020 and early 2021, with significant cash outflows for acquisitions such as preCARDIA and Breethe. These acquisitions correspond with large contingent consideration changes and fair value adjustments affecting the financial statements.
Operating assets and liabilities
Changes in accounts receivable, inventories, and other working capital components exhibit significant volatility, with episodes of both increases and decreases suggesting fluctuations in collection cycles, inventory management, and prepaid expenses. Particularly, accounts receivable and inventories show large negative movements in some quarters, indicating potential pressure on working capital.
Net cash provided by operating activities
Operating cash flow remains generally strong, with consistent positive cash generation in most quarters. Peaks occur in late 2019 and mid-2021, though some quarters demonstrate lower inflows, possibly due to working capital fluctuations or net income variability.
Investing activities
Investing cash flow is predominantly negative, indicative of ongoing investments in marketable securities, property, and equipment, as well as acquisitions. Occasional positive cash inflows from sales or maturities of marketable securities partially offset these outflows. Some quarters experience extremely large outflows, especially during acquisition periods.
Financing activities
Financing cash flows are inconsistent, with both inflows from stock option exercises and employee stock purchase plans, and significant outflows related to repurchases of common stock, payment of contingent considerations, and taxes related to stock settlements. Large repurchase programs are evident in late 2018 and continuing sporadically through 2022. The overall pattern reflects active capital management and shareholder return strategies.
Cash and cash equivalents changes
Quarterly net changes in cash demonstrate variability, with some quarters showing substantial increases while others experience sizeable reductions. The fluctuations correspond closely with the interplay of operating cash generation, investing outflows for acquisitions and capital expenditures, and financing activities, including stock repurchases and issuance.